Currently, the understanding of lung neuroendocrine cancer centers on SCLC and carcinoids representing entirely unrelated tumor entities, occurring in distinct patient populations (younger, never-smokers for carcinoids vs. older smokers for SCLC), and characterized by highly distinct genomic profiles, most notably separated by RB1 and TP53 genomic status and TMB (12). The gene discussed is TP53; the disease is small cell lung carcinoma.